Identifying advanced glycation end products as a major source of oxidants in aging: implications for the management and/or prevention of reduced renal function in elderly persons.

[1]  R. Foley,et al.  Long-term consequences of kidney donation. , 2009, The New England journal of medicine.

[2]  L. Ferrucci,et al.  Protection against loss of innate defenses in adulthood by low advanced glycation end products (AGE) intake: role of the antiinflammatory AGE receptor-1. , 2009, The Journal of clinical endocrinology and metabolism.

[3]  W. Weimar,et al.  Long-term consequences of kidney donation. , 2009, The New England journal of medicine.

[4]  S. Bandinelli,et al.  Predictivity of survival according to different equations for estimating renal function in community-dwelling elderly subjects. , 2008, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[5]  G. Striker,et al.  Oral glycotoxins determine the effects of calorie restriction on oxidant stress, age-related diseases, and lifespan. , 2008, The American journal of pathology.

[6]  A. Go,et al.  The risk of acute renal failure in patients with chronic kidney disease. , 2008, Kidney international.

[7]  L. Ferrucci,et al.  High basal metabolic rate is a risk factor for mortality: the Baltimore Longitudinal Study of Aging. , 2008, The journals of gerontology. Series A, Biological sciences and medical sciences.

[8]  J. Uribarri,et al.  Endothelial dysfunction in patients with chronic kidney disease results from advanced glycation end products (AGE)-mediated inhibition of endothelial nitric oxide synthase through RAGE activation. , 2008, Clinical journal of the American Society of Nephrology : CJASN.

[9]  G. Striker,et al.  Glycotoxins in the diet promote diabetes and diabetic complications , 2007, Current diabetes reports.

[10]  G. Striker,et al.  Reduced oxidant stress and extended lifespan in mice exposed to a low glycotoxin diet: association with increased AGER1 expression. , 2007, The American journal of pathology.

[11]  L. Ferrucci,et al.  Circulating glycotoxins and dietary advanced glycation endproducts: two links to inflammatory response, oxidative stress, and aging. , 2007, The journals of gerontology. Series A, Biological sciences and medical sciences.

[12]  G. Striker,et al.  Combined AGE inhibition and ACEi decreases the progression of established diabetic nephropathy in B6 db/db mice. , 2006, Kidney International.

[13]  G. Striker,et al.  Differential effects of continuous and intermittent 17beta-estradiol replacement and tamoxifen therapy on the prevention of glomerulosclerosis: modulation of the mesangial cell phenotype in vivo. , 2006, The American journal of pathology.

[14]  Z. Varghese,et al.  PPARα agonist fenofibrate improves diabetic nephropathy in db/db mice. Commentary , 2006 .

[15]  Anne B. Newman,et al.  Chronic Kidney Disease and Functional Limitation in Older People: Health, Aging and Body Composition Study , 2006, Journal of the American Geriatrics Society.

[16]  G. Striker,et al.  PPARalpha agonist fenofibrate improves diabetic nephropathy in db/db mice. , 2006, Kidney international.

[17]  S. Genuth,et al.  Glycation and carboxymethyllysine levels in skin collagen predict the risk of future 10-year progression of diabetic retinopathy and nephropathy in the diabetes control and complications trial and epidemiology of diabetes interventions and complications participants with type 1 diabetes. , 2005, Diabetes.

[18]  David E. Misek,et al.  Podocyte hypertrophy, "adaptation," and "decompensation" associated with glomerular enlargement and glomerulosclerosis in the aging rat: prevention by calorie restriction. , 2005, Journal of the American Society of Nephrology : JASN.

[19]  G. Striker,et al.  Glomerular aging in females is a multi-stage reversible process mediated by phenotypic changes in progenitors. , 2005, The American journal of pathology.

[20]  H. Vlassara.  Advanced Glycation in Health and Disease: Role of the Modern Environment , 2005, Annals of the New York Academy of Sciences.

[21]  B. Hudson,et al.  Pyridoxamine as a multifunctional pharmaceutical: targeting pathogenic glycation and oxidative damage , 2005, Cellular and Molecular Life Sciences CMLS.

[22]  M. Laakso,et al.  High Serum Levels of Advanced Glycation End Products Predict Increased Coronary Heart Disease Mortality in Nondiabetic Women but not in Nondiabetic Men: A Population-Based 18-Year Follow-Up Study , 2005, Arteriosclerosis, thrombosis, and vascular biology.

[23]  A. Murray,et al.  Chronic kidney disease and the risk for cardiovascular disease, renal replacement, and death in the United States Medicare population, 1998 to 1999. , 2005, Journal of the American Society of Nephrology : JASN.

[24]  G. Striker,et al.  The glomerulosclerosis of aging in females: contribution of the proinflammatory mesangial cell phenotype to macrophage infiltration. , 2004, The American journal of pathology.

[25]  J. Li,et al.  Development of albuminuria and glomerular lesions in normoglycemic B6 recipients of db/db mice bone marrow: the role of mesangial cell progenitors. , 2004, Diabetes.

[26]  J. He,et al.  Advanced glycation endproduct (AGE) receptor 1 is a negative regulator of the inflammatory response to AGE in mesangial cells. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[27]  E. Stadtman.  Role of oxidant species in aging. , 2004, Current medicinal chemistry.

[28]  J. Uribarri,et al.  Glycoxidation and inflammation in renal failure patients. , 2004, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[29]  S. Bandinelli,et al.  Diverse Effect of Inflammatory Markers on Insulin Resistance and Insulin‐Resistance Syndrome in the Elderly , 2004, Journal of the American Geriatrics Society.

[30]  J. Morrow,et al.  Increased prevalence of oxidant stress and inflammation in patients with moderate to severe chronic kidney disease. , 2004, Kidney international.

[31]  G. Striker,et al.  Response to sex hormones differs in atherosclerosis-susceptible and -resistant mice. , 2003, American journal of physiology. Endocrinology and metabolism.

[32]  G. Striker,et al.  Glucose induces clonal selection and reversible dinucleotide repeat expansion in mesangial cells isolated from glomerulosclerosis-prone mice. , 2003, Diabetes.

[33]  J. Gore,et al.  Creatinine clearance and adverse hospital outcomes in patients with acute coronary syndromes: findings from the global registry of acute coronary events (GRACE) , 2003, Heart.

[34]  E. Fisher,et al.  Dietary glycotoxins promote diabetic atherosclerosis in apolipoprotein E-deficient mice. , 2003, Atherosclerosis.

[35]  G. Striker,et al.  Estrogen deficiency accelerates progression of glomerulosclerosis in susceptible mice. , 2003, The American journal of pathology.

[36]  L. Ferrucci,et al.  Insulin-like growth factor I and interleukin-6 contribute synergistically to disability and mortality in older women. , 2003, The Journal of clinical endocrinology and metabolism.

[37]  G. Striker,et al.  Resistance to glomerulosclerosis in B6 mice disappears after menopause. , 2003, The American journal of pathology.

[38]  J. Uribarri,et al.  Restriction of dietary glycotoxins reduces excessive advanced glycation end products in renal failure patients. , 2003, Journal of the American Society of Nephrology : JASN.

[39]  H. Bosshart.  Interleukin-3 receptors in Hodgkin's disease. , 2003, The American journal of pathology.

[40]  G. Eknoyan,et al.  Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey. , 2003, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[41]  M. Peppa,et al.  Inflammatory mediators are induced by dietary glycotoxins, a major risk factor for diabetic angiopathy , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[42]  G. Striker,et al.  Estrogen-related abnormalities in glomerulosclerosis-prone mice: reduced mesangial cell estrogen receptor expression and prosclerotic response to estrogens. , 2002, The American journal of pathology.

[43]  G. Striker,et al.  Upregulation of type I collagen by TGF-β in mesangial cells is blocked by PPARγ activation , 2002 .

[44]  L. Ferrucci,et al.  Peripheral Blood Markers of Inflammation Predict Mortality and Functional Decline in High‐Functioning Community‐Dwelling Older Persons , 2002, Journal of the American Geriatrics Society.

[45]  G. Striker,et al.  Reversibility of glucose-induced changes in mesangial cell extracellular matrix depends on the genetic background. , 2002, Diabetes.

[46]  G. Striker,et al.  Autocrine activation of the IGF-I signaling pathway in mesangial cells isolated from diabetic NOD mice. , 2002, Diabetes.

[47]  G. Striker,et al.  Glomerulosclerosis is transmitted by bone marrow-derived mesangial cell progenitors. , 2001, The Journal of clinical investigation.

[48]  H. Vlassara.  The AGE‐receptor in the pathogenesis of diabetic complications , 2001, Diabetes/metabolism research and reviews.

[49]  A. Schmidt,et al.  The multiligand receptor RAGE as a progression factor amplifying immune and inflammatory responses. , 2001, The Journal of clinical investigation.

[50]  G. Striker,et al.  Pentosan polysulfate prevents glomerular hypertension and structural injury despite persisting hypertension in 5/6 nephrectomy rats. , 2001, Journal of the American Society of Nephrology : JASN.

[51]  T. Koschinsky,et al.  Presence of Diabetic Complications in Type 1 Diabetic Patients Correlates with Low Expression of Mononuclear Cell AGE-Receptor-1 and Elevated Serum AGE , 2001, Molecular medicine.

[52]  J. Himmelfarb,et al.  Manifestations of Oxidant Stress in Uremia , 2000, Blood Purification.

[53]  A. Schmidt,et al.  The biology of the receptor for advanced glycation end products and its ligands. , 2000, Biochimica et biophysica acta.

[54]  N. Holbrook,et al.  Oxidants, oxidative stress and the biology of ageing , 2000, Nature.

[55]  J. Baynes,et al.  Glycoxidation and lipoxidation in atherogenesis. , 2000, Free radical biology & medicine.

[56]  H. Cohen,et al.  Associations of elevated interleukin-6 and C-reactive protein levels with mortality in the elderly. , 1999, The American journal of medicine.

[57]  J. Baynes,et al.  Role of oxidative stress in diabetic complications: a new perspective on an old paradigm. , 1999, Diabetes.

[58]  M. Huijberts,et al.  Breakers of advanced glycation end products restore large artery properties in experimental diabetes. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[59]  C. Baylis,et al.  The aging kidney: insights from experimental studies. , 1998, Journal of the American Society of Nephrology : JASN.

[60]  R. Bucala,et al.  Orally absorbed reactive glycation products (glycotoxins): an environmental risk factor in diabetic nephropathy. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[61]  N. Hotta,et al.  Rapid formation of advanced glycation end products by intermediate metabolites of glycolytic pathway and polyol pathway. , 1996, Biochemical and biophysical research communications.

[62]  Paul J Thornalley.  Pharmacology of methylglyoxal: formation, modification of proteins and nucleic acids, and enzymatic detoxification--a role in pathogenesis and antiproliferative chemotherapy. , 1996, General pharmacology.

[63]  H. Vlassara,et al.  Protein glycation in the kidney: role in diabetes and aging. , 1996, Kidney international.

[64]  R. Bucala,et al.  Prevention of cardiovascular and renal pathology of aging by the advanced glycation inhibitor aminoguanidine. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[65]  A. Schmidt,et al.  Cellular receptors for advanced glycation end products. Implications for induction of oxidant stress and cellular dysfunction in the pathogenesis of vascular lesions. , 1994, Arteriosclerosis and thrombosis : a journal of vascular biology.

[66]  K. Kuwabara,et al.  Receptor for advanced glycation end products (AGEs) has a central role in vessel wall interactions and gene activation in response to circulating AGE proteins. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[67]  R. Bucala,et al.  Lipid advanced glycosylation: pathway for lipid oxidation in vivo. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[68]  N W Shock,et al.  Longitudinal Studies on the Rate of Decline in Renal Function with Age , 1985, Journal of the American Geriatrics Society.